1 Characteristics of children readmitted with severe pneumonia in Kenyan hospitals 2 Diana Marangu-Boore<sup>1</sup>, Paul Mwaniki<sup>2</sup>, Lynda Isaaka<sup>2</sup>, Teresiah Njoroge<sup>2</sup>, Livingstone 3 Mumelo<sup>2</sup>, Dennis Kimego<sup>2</sup>, Achieng Adem<sup>3</sup>, Elizabeth Jowi<sup>4</sup>, Angeline Ithondeka<sup>5</sup>, Conrad Wanyama<sup>2</sup>, Ambrose Agweyu<sup>2,6</sup> on behalf of the CIN Author Group\* 4 5 6 Affiliations: 7 <sup>1</sup> Paediatric Pulmonology Division, Department of Paediatrics and Child Health, University of 8 Nairobi, Nairobi, Kenya 9 <sup>2</sup> Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, 10 Nairobi, Kenya 11 <sup>3</sup> Department of Health, Kisumu County, Kenya 12 <sup>4</sup> Department of Health, Nairobi County, Kenya 13 <sup>5</sup> Department of Health, Nakuru County, Kenya 14 <sup>6</sup> Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical 15 Medicine, London, UK 16 17 \*Correspondence: 18 Diana Marangu-Boore 19 dmarangu@uonbi.ac.ke 20 21 22 23 24 25 26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**Abstract** 

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

**Background:** Pneumonia is a leading cause of childhood morbidity and mortality. Hospital readmission may signify missed opportunities for care or undiagnosed comorbidities.

Methods: We conducted a retrospective cohort study including children aged ≥2 months to 14 years hospitalised with severe pneumonia between 2013 and 2021 in a network of 22 primary referral hospitals in Kenya. Severe pneumonia was defined using the World Health Organization criteria, and re-admission was based on clinical documentation from individual patient case notes. We estimated the prevalence of re-admission, described clinical management practices, and modelled risk factors for re-admission and inpatient mortality.

Results: Among 20,603 children diagnosed with severe pneumonia, 2,274 (11.0%, 95%) confidence interval (CI) 10.62 to 11.47) were readmitted. Re-admission was independently associated with age (12-59 months vs 2-11 months: adjusted odds ratio (aOR) 1.70, 95% confidence interval (CI) 1.55 to 1.88; >5 years vs 2-11 months: aOR 1.86, 95% CI 1.55 to 2.23), malnutrition (weight for age z-score (WAZ) <-3SD vs WAZ> -2SD: aOR 2.03, 95%1.83 to 2.28); WAZ -2 to -3 SD vs WAZ> -2SD: aOR 1.37, 95% CI 1.20 to 1.56) and presence of a concurrent neurological disorder (aOR 4.04, 95% CI 1.57 to 10.42). Chest radiography was ordered more frequently among those readmitted (540/2,274 vs 3,102/18,329, p<0.001). Readmitted patients were more likely to receive second-line antibiotics (808/2,256 vs 5,538/18,173 p<0.001), TB medication (69/2,256 vs 298/18,173 p<0.001), salbutamol (530/2,256 vs 3,707/18,173 p=0.003), and prednisolone (157/2,256 vs 764/18,173 p<0.001). Inpatient mortality was 2,354/18,329 (12.8%) among children admitted with a first episode of severe pneumonia and 269/2,274 (11.8%) among those who were readmitted (adjusted hazard ratio (aHR) 0.94, 95% CI 0.82-1.07). Age (12-59 months vs 2-11 months: aHR 0.62, 95% 0.57 to 0.67), female sex (aHR 1.23, 95% 1.14 to 1.33), malnutrition (WAZ <-3SD vs WAZ> -2SD: aHR 1.90 95% CI 1.74 to 2.08); WAZ -2 to -3 SD vs WAZ> -2SD: aHR 1.48, 95%

CI 1.32 to 1.65), incomplete vaccination (aHR 1.43, 95% CI 1.16 to 1.75), and anaemia (aHR 2.16, 95% CI 1.90 to 2.45) were independently associated with mortality. Conclusions: Children readmitted with severe pneumonia account for a substantial proportion of pneumonia hospitalisations and deaths. Further research is required to develop evidence-based approaches to screening, case management, and follow-up of children with severe pneumonia, prioritising those with underlying risk factors for readmission and mortality. Keywords: Lower respiratory tract infections; Paediatrics; Adolescents; Low-and-middleincome countries; Africa; recurrent pneumonia; persistent pneumonia

Background

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

many low-and-middle-income-countries (LMICs), children and adolescents disproportionately face the double burden of acute respiratory infectious diseases and chronic comorbidities, resulting in long-term impairment of lung function (1, 2), reduced quality of life (3), and mortality (4). Presence of chronic comorbidities and prior severe pneumonia episodes increase the risk of pneumonia re-admission and is associated with substantial costs (5, 6). Almost 10% of children with community acquired pneumonia have recurrent pneumonia (7, 8). Recurrent pneumonia is defined as at least two episodes of pneumonia in one year or three episodes ever, with interval radiographic clearing of opacities; whereas persistent pneumonia is characterized by persistence of symptoms and radiographic abnormalities for more than one month (9). Recurrent and persistent pneumonia have varied aetiologies that are known antecedents to bronchiectasis or childhood interstitial lung disease (8, 10, 11), including rare genetic conditions that are increasingly being reported in sub Saharan Africa (12-14). Obstructive airway disease in children hospitalised with severe pneumonia may be underdiagnosed, and other differential diagnoses may not be considered (15, 16). While predictors of repeated acute hospitalisation for paediatric asthma which tends to co-exist with pneumonia are known and relatively modifiable, those for severe pneumonia readmission in sub-Saharan Africa are lacking (17).

The World Health Organization (WHO) guidelines for pneumonia used in many LMICs comprise a syndromic approach to disease classification and management to enable health workers at the first level referral hospitals to provide basic care for young children (18). However, the validity of the syndromic approach to pneumonia classification and management has yet to be tested among children presenting for severe illness after a previous episode of hospitalisation. Robust data on inpatient management of children with repeated hospitalisation for severe pneumonia are needed to guide appropriate policy recommendations on preventive, diagnostic, treatment and follow-up measures to optimize care and outcomes.

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

The aims of this study were to: i) establish the proportion of children aged 2 months to 14 years who were re-admitted with severe pneumonia in an established network of Kenyan public hospitals; ii) determine the factors associated with severe pneumonia re-admissions in this population; iii) describe the investigations and treatment provided to children re-admitted with severe pneumonia; and iv) explore the risk factors associated with mortality among these children. **Methods** Reporting The reporting of this observational study follows the Strengthening of Reporting of Observational studies in Epidemiology (STROBE) statement (19). Ethics, consent and permissions The Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit approved the collection of the deidentified data analysed in this study and waived the requirement for individual informed consent from patients whose data were used for this research. The Clinical Information Network (CIN) is run in collaboration with the Kenya Paediatric Association. Ministry of Health, and participating hospitals with the aim to improving routine clinical documentation for quality improvement, and for observational and interventional research (20).Study design and setting We undertook a retrospective cohort study involving patients admitted to CIN hospitals. The CIN was initiated in October 2013 and comprises 22 purposefully selected county hospitals distributed across the densely populated central and western regions of Kenya (21, 22).

Patients are admitted by a junior clinician under the supervision of one or more hospital

paediatricians. CIN implements the use of structured clinical forms for all admitted children, capturing biodemographic data, caregiver-reported medical history, including whether the patient was readmitted and vaccination status according to the national routine schedule, clinical signs, diagnoses, diagnostic tests ordered, treatment plan, and inpatient outcome. Decisions on clinical and nursing management are made at the discretion of hospital staff with access to basic laboratory and radiological services. Case management is based on the Kenya national paediatric guidelines (23) adapted from WHO guidelines (18) as a reference. Patients are reviewed at least once daily for clinical progress. At hospital discharge, caregivers receive instructions on correct administration of continuing treatments and a follow up outpatient clinic visit is scheduled typically within two weeks.

#### Study participants, data sources and variables

The study population comprised all children admitted to paediatric wards in CIN hospitals. Children hospitalised with a documented diagnosis of pneumonia were included. Children aged less than 2 months or more than 14 years, and those without severe pneumonia defined using the World Health Organization criteria between 2013 and 2021 were excluded. Trained data clerks extract deidentified individual patient data from routine hospital records into a REDCap upon discharge (22, 24). For this analysis, data retrieved comprised: the patient's unique identifier, age, sex, hospital unique identifier, prior pneumonia admission (we could not compute the time from the first admission given the nature of the data), known comorbidities or risk factors such as malnutrition, anaemia, chronic neurological disorder, asthma, cardiac disease, renal disease, HIV, TB and sickle cell disease. We also extracted clinical data comprising management instituted during hospitalisation such as routine laboratory investigations e.g. full blood count; plain chest radiography; supportive treatment e.g. oxygen supplementation; antimicrobials treatment (first line, second line, third line antibiotics, coverage for atypical pathogens, antitubercular and antifungal medications); inhaled or systemic corticosteroids; and outcomes including discharge, referral or death. It should be

noted that the structured forms used in CIN to document diagnostics and treatments only record affirmative entries (i.e., "Yes," "Ordered," or "Prescribed"). As a result, we inferred that entries which were not recorded on the forms were negative.

# Statistical analysis

Data were exported to STATA (StataCorp. 2019. *Stata Statistical Software: Release 16.1* College Station, TX: StataCorp LLC.) for statistical analysis. Descriptive statistics were summarized as frequencies with percentages for categorical data, means with standard deviations for continuous data that were normal and medians with interquartile range for continuous data that were skewed. We estimated the proportion of severe pneumonia readmissions among children aged 2 months to 14 years hospitalised within the CIN.

A multivariable mixed-effects logistic model was fitted to determine factors associated with readmission among patients with severe pneumonia in this clinical cohort and we reported adjusted risk ratios. CIN data are hierarchical because admission episodes are nested within 22 hospitals, thus we used a random intercept logistic regression model to account for clustering (25). In the formula that follows,  $Y_{ij}$  denotes pneumonia readmission for the  $i^{th}$  child admitted in the  $j^{th}$  hospital ( $Y_{ij}$  = 1 denotes pneumonia readmission, while  $Y_{ij}$  = 0 denotes no pneumonia readmission);  $X_{1ij}$ , through  $X_{kij}$  denote the k explanatory variables measured on the  $i^{th}$  child admitted in the  $j^{th}$  hospital (e.g., child's age); and  $\alpha_{0j}$  denotes the unobserved cluster effect. Our model had no hospital level variables. It incorporates cluster-specific random effects to account for the within-cluster correlation of patient outcomes.

logit(Pr(
$$Y_{ij} = 1$$
)) =  $\alpha_0 + \alpha_{0j} + \alpha_1 x_{1ij} + \cdots + \alpha_k x_{kij}$  where  $\alpha_{0j} \sim N(0, \tau^2)$ .

The assumption is made that the random effects are independent of the model covariates (X).

Explanatory variables included age, sex, weight-for-age z- score (WAZ), vaccination status,

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

previous wheeze and comorbidities including anaemia, HIV, TB, and neurological disorders. The Stata command "or:xtmelogit" was used to fit the random intercept model. To determine factors associated with mortality among children with severe pneumonia readmissions, we fitted a multivariable mixed-effects Cox proportional hazard model (shared gamma frailty model) and reported adjusted hazard ratios with corresponding 95% confidence intervals. In the formula that follows, α denotes the random effect associated with the j-th hospital. The shared frailty term has a multiplicative effect on the baseline hazard function: hi (t) =  $h_0(t) \exp(\alpha_i) \exp(\mathbf{X}_i \beta)$  (26). Explanatory variables included age, sex, weight-for-age zscore (WAZ), vaccination status, previous wheeze and comorbidities including anaemia, HIV. TB, and neurological disorders. We generated Cox proportional hazard regression plots for survival by type of pneumonia admission (first episode pneumonia and pneumonia rehospitalisation); by age group (under 12 months, 12-59 months and over 5's), gender, WAZ category (<-3 SD, -2 to -3 SD, >-2SD), vaccination and anaemia status. The Stata command "stcox" was used to fit the shared frailty Cox proportional hazard model. Censoring occurred at the time of death, discharge or referral, whichever came first. For all models, explanatory variables were selected a priori based on existing literature, clinical relevance with regard to effect on outcome, ease of identification for risk stratification, and biological plausibility. P-values were rounded to three decimal places and were deemed statistically significant if they were <0.05 (2-sided). To handle missing data, we performed multiple imputation by chained equations generating 10 imputed datasets under the assumption that data were missing at random (27). Results Out of 49,872 children admitted with pneumonia during the study period, 29,269 (59%) were excluded from the analysis. Exclusions were 27,977 children who did not have severe pneumonia, and 1,292 children aged < 2 months or > 14 years. Figure 1 shows the study population inclusion process. The main variables with missing values were gender, which was

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

missing for 127 children (0.62%), and vaccination status which was missing for 13,468 children (65%). Figure 1: STROBE Flow Chart Flow diagram of eligible study participants. Proportion of children re-admitted with severe pneumonia Of the population included in the analysis comprising 20,603 children aged 2 months to 14 years hospitalised with severe pneumonia over the study period, 2,274 were readmitted, giving an estimated prevalence of 11.0% (95% 10.62-11.47) for readmissions among children with severe pneumonia. Characteristics of study participants The median age of the study population was 12 months (IQR 6.0-24.0), 9,907/20,603 (48%) of children were under 12 months of age, 9,287/20,603 (45%) of the children were aged 12-59 months and 1,409/20,603 (6.8%) were aged 5-14 years. The majority of children were reported to be up to date with their vaccination status 6,950/7,135 (97%). However, most were severely or moderately underweight 17,018/20,603 (83%). Compared to children admitted for the first time with severe pneumonia, children re-admitted with severe pneumonia were slightly older (median age 14.4 months vs 12 months), underweight (median WAZ score -1.7 vs -1.1), were diagnosed with TB (1.8% vs 0.7%), and neurological disorders (0.4% vs 0.12%) more frequently (Table 1).

#### Table 1: Admission characteristics of study participants 241

Indicator	Levels	Total	Severe	Severe	p-value
			Pneumonia	Pneumonia	
			1 <sup>st</sup> Admission	Readmission	
		20,603	18,329	2,274	
Age months Median		12.0 (6.0-24.0)	12.0 (6.0-24.0)	14.4 (9.6-28.8)	<0.001
(IQR)					
	Missing	0	0	0	
(%)	<12mo	9,907 (48.1)	9,078 (49.5)	829 (36.5)	<0.001
	12-59mo	9,287 (45.1)	8,030 (43.8)	1,257 (55.3)	
	Over 5yrs	1,409 (6.8)	1,221 (6.7)	188 (8.3)	
	Missing	0	0	0	
Gender (%)	Male	11,334 (55.4)	10,049 (55.2)	1,285 (56.8)	0.13
	Missing	127 (0.62)	114 (0.63)	13 (0.57)	
WAZ Median (IQR)		-1.1(-2.46, -0.46)	-1.1(-2.40, -0.03)	-1.7(-3.25, -0.51)	<0.001
	Missing	812	718	94	
(%)	<-3SD	14,225 (69.0)	12,914 (70.5)	1,311 (57.7)	<0.001
	-2 to -3SD	2,793 (13.6)	2,443 (13.3)	350 (15.4)	
	>-2SD	3,584 (17.4)	2,972 (16.2)	613 (27.0)	
	Missing	0	0	0	
Vaccination	Up to date	6,950 (97.4)	6,145 (97.5)	805 (96.9)	0.3
	Missing	13,468 (65.37)	12,025 (65.61)	1,443 (63.46)	
Wheeze	Present	3,240 (16.2)	2,874 (16.1)	805 (16.6)	0.54
	Missing	545 (2.65)	475 (2.59)	70 (3.08)	
Anaemia	Present	1,000 (4.9)	909 (5.0)	91 (4.0)	0.045

	Missing	0	0	0	
HIV	Positive or	231 (1.1)	197 (1.1)	34 (1.5)	0.073
	Exposed				
	Missing	1	1	0	
ТВ	Positive	161 (0.8)	120 (0.7)	41 (1.8)	<0.001
	Missing	0	0	0	
Neurological disorder	Present	22 (0.1)	12 (0.01)	10 (0.4)	<0.001
	Missing	0	0	0	
Saturations <90%		7,717 (37.5)	6,946 (37.9)	771 (33.9)	<0.001

WAZ weight-for-age Z-score; Abnormal WAZ <-2SD

Neurological disorder: cerebral palsy, convulsive disorder or epilepsy

Factors associated with severe pneumonia re-admissions Age (12-59 months vs 2-11 months: adjusted odds ratio (aOR) 1.70, 95% 1.55 to 1.88), over 5 years vs 2-11 months: aOR 1.86, 95% 1.55 to 2.23), severe malnutrition (WAZ <-3SD vs WAZ> -2SD) (aOR 2.03, 95%1.83 to 2.28), moderate malnutrition (WAZ <-3SD vs WAZ> -2SD) (aOR 1.37, 95%1.20 to 1.56), and neurological disorder (aOR 4.04, 95% 1.57 to 10.42) were independent risk factors for re-admission adjusting for gender, vaccination status, any wheeze, anaemia, HIV disease and TB (Table 2).

# Table 2: Risk factors for readmission among study participants

Factor	Adjusted odds ratio	p-value
	(95% confidence interval)	
Age (ref: <12 months)		
12-59 months	1.70 (1.55-1.88)	<0.0001
Over 5yrs	1.86 (1.55-2.23)	<0.0001
Gender (ref: female)	1.04 (0.95-1.14)	0.372
WAZ (ref: >-2SD)		
-2 to -3SD	1.37 (1.20-1.56)	<0.0001
<-3SD	2.04 (1.83-2.28)	<0.0001
Vaccination (ref: incomplete)	0.74 (0.50-1.08)	0.116
Wheeze (ref: absent)	1.49 (0.63-3.52)	0.367
Anaemia (ref: absent)	0.96 (0.76-1.22)	0.744
HIV (ref: negative)	1.15 (0.77-1.72)	0.492
TB (ref: absent)	1.36 (0.91-2.02)	0.129
Neurological disorder (ref: absent)	4.04 (1.57-10.42)	0.004

- Number of imputations=10; Number of observations=20,602; Number of groups=20;
- Outcome = severe pneumonia readmission.
- Imputed variables = gender 127; vaccination 13,468.
- WAZ weight-for-age Z-score

Investigations and treatment provided to study participants Compared to children admitted for the first time with severe pneumonia, children re-admitted with severe pneumonia had chest radiography performed more frequently (24% vs 17%, p<0.001); and more prescriptions for second line antibiotics, specifically ceftriaxone (36% vs 30%, p<0.001), TB treatment (3% vs 1.6%, p<0.001), salbutamol (23% vs 20%, p=0.003) and prednisone (7% vs 4%, p<0.001) (Table 3).

Table 3: Diagnostics and treatments used among study participants

	Total(N=20,603)	Severe Pneumonia	Severe Pneumonia	p-value
		First Admission (N=18,329)	Readmission (N=2,274)	
Yes	13,245 (64.3)	11,940 (65.1)	1,305 (57.4)	<0.001
No	7,358 (35.7)	6,389 (34.9)	969 (42.7)	
Yes	3,642 (17.7)	3,102 (16.9)	540 (23.8)	<0.001
No	16,961 (82.3)	15,227 (83.1)	1,734 (76.3)	
Yes	5,839 (28.3)	5,216 (28.5)	623(27.4)	0.540
No	14,764 (71.7)	13,113 (71.5)	1,651 (72.6)	
Yes	16,376 (79.5)	14,721 (80.3)	1,655 (72.8)	<0.001
No	4,227 (20.5)	3,608 (19.7)	619 (27.2)	
Yes	14,613 (70.9)	13,233 (72.2)	1,380 (60.7)	<0.001
No	5,990 (29.1)	5,096 (27.8)	894 (39.3)	
Yes	1,220 (5.9)	1,104 (6.0)	116 (5.1)	0.20
	No Yes No Yes No Yes No Yes No	Yes 13,245 (64.3) No 7,358 (35.7) Yes 3,642 (17.7) No 16,961 (82.3)  Yes 5,839 (28.3) No 14,764 (71.7)  Yes 16,376 (79.5) No 4,227 (20.5) Yes 14,613 (70.9) No 5,990 (29.1)	First Admission (N=18,329)  Yes 13,245 (64.3) 11,940 (65.1)  No 7,358 (35.7) 6,389 (34.9)  Yes 3,642 (17.7) 3,102 (16.9)  No 16,961 (82.3) 15,227 (83.1)  Yes 5,839 (28.3) 5,216 (28.5)  No 14,764 (71.7) 13,113 (71.5)  Yes 16,376 (79.5) 14,721 (80.3)  No 4,227 (20.5) 3,608 (19.7)  Yes 14,613 (70.9) 13,233 (72.2)  No 5,990 (29.1) 5,096 (27.8)	Yes       13,245 (64.3)       11,940 (65.1)       1,305 (57.4)         No       7,358 (35.7)       6,389 (34.9)       969 (42.7)         Yes       3,642 (17.7)       3,102 (16.9)       540 (23.8)         No       16,961 (82.3)       15,227 (83.1)       1,734 (76.3)         Yes       5,839 (28.3)       5,216 (28.5)       623(27.4)         No       14,764 (71.7)       13,113 (71.5)       1,651 (72.6)         Yes       16,376 (79.5)       14,721 (80.3)       1,655 (72.8)         No       4,227 (20.5)       3,608 (19.7)       619 (27.2)         Yes       14,613 (70.9)       13,233 (72.2)       1,380 (60.7)         No       5,990 (29.1)       5,096 (27.8)       894 (39.3)

	No	19,383 (94.1)	17,225 (94.0)	2,158 (94.9)	
Second line antibiotics					
Ceftriaxone	Yes	6,346 (30.8)	5,538 (30.2)	808 (35.5)	<0.001
	No	14,257 (69.2)	12,791 (69.8)	1,466 (64.5)	
Other antimicrobials					
Metronidazole	Yes	1,002 (4.9)	894 (4.9)	108 (4.7)	0.92
	No	19,601 (95.1)	17,435 (95.1)	2,166 (95.3)	
Cotrimoxazole	Yes	538 (2.6)	480 (2.6%)	58 (2.6)	0.94
	No	20,065 (97.4)	17,849 (97.4)	2,216 (97.4)	
TB medication	Yes	367 (1.8)	298 (1.6%)	69 (3.0)	<0.001
	No	20,236 (98.2)	17,875 (98.4)	2,205 (97.0)	
Other treatment					
Salbutamol	Yes	4,237 (20.6)	3,707 (20.2)	530 (23.3)	0.003
	No	16,366 (79.4)	14,622 (79.8)	1,744 (76.7)	
Prednisolone	Yes	921 (4.5)	764 (4.2%)	157 (6.9)	<0.001
	No	19,682 (95.5)	17,565 (95.8)	2,177 (93.1)	

Outcomes of study participants The median length of hospital stay was 4 days IQR (2-7) for children hospitalised with a severe pneumonia for the first time; and 5 days IQR (3-8) for children readmitted with severe pneumonia. We noted that children readmitted with severe pneumonia were hospitalised for longer than seven days more frequently than those admitted for the first time with severe pneumonia (34% vs 26%, p<0.001). Among 18,329 children admitted with severe pneumonia for the first time, 2,354 (12.8% [12.37-13.33]) died during their hospital stay, while 269 (11.8% [10.56-13.22]) of 2,274 children readmitted with severe pneumonia died during their hospital stay (Table 4).

# Table 4: Outcomes of study participants

	Total(N=20,603)	Severe Pneumonia	Severe Pneumonia	p-value
		First Admission (N=18,329)	Readmission (N=2,274)	
Length of stay				
Median [IQR] (Range) days	4 [2-7] (1,401)	4 [2-7] (1,339)	5 [3-8] (1,401)	
Missing	1	1	0	
Less than 7 days	15,159 (73.6)	13,650 (74.5)	1,509 (66.4)	<0.001
7 days or more	5,444 (26.4)	4,679 (25.5)	765 (33.6)	
Missing	0	0	0	
Discharged	17,261 (83.8)	15,337 (83.7)	1,924 (84.6)	0.18
Referred	641 (3.1)	567 (3.1)	74 (3.3)	
Died	2,623 (12.7)	2,354 (12.8)	269 (11.8)	
Missing	78 (0.4)	71 (0.4)	7 (0.3)	

Risk factors associated with mortality Age <12 months (adjusted HR (aHR) 1.63, 95% 1.49 to 1.77), age >5 years (aHR 1.52, 95% 1.31 to 1.77), female gender (aHR 1.23, 95% 1.14 to 1.33), severe malnutrition (aHR 1.90 95% 1.74 to 2.08), moderate malnutrition (aHR 1.48, 95% 1.32 to 1.65), incomplete vaccination (aHR 1.43, 95% 1.16 to 1.75) and anaemia (aHR 2.16, 95% 1.90 to 2.45) were independently associated with mortality amongst children admitted with severe pneumonia when adjusted for gender, any wheeze, HIV, TB and a neurological disorder (Table 5 and Figure 2). Figure 2: Cox proportional hazard plots for mortality among study participants

# Table 5: Factors associated with mortality among children admitted with severe pneumonia in

### Kenyan hospitals within the Clinical Information Network (CIN)

Factor	Adjusted hazard ratio (95% CI)	p-value
Pneumonia re-admission (ref: first episode pneumonia)	0.94 (0.82-1.07	0.338
Age (ref: <12 months)		
12-59 months	0.62 (0.57-0.67)	<0.0001
Over 5yrs	0.94 (0.81-1.08)	0.379
Gender (ref: male)	1.23 (1.14-1.33)	<0.0001
WAZ (ref: >-2SD)		
-2 to -3SD	1.48 (1.32-1.65)	<0.0001
<-3SD	1.90 (1.74-2.08)	<0.0001
Vaccination not up to date (ref: complete)	1.43 (1.16-1.75)	0.001
Wheeze present (ref: absent)	0.21 (0.03-1.50)	0.120
Anaemia present (ref: absent)	2.16 (1.90-2.45)	<0.0001
HIV infected/exposed (ref: negative)	1.10 (0.84-1.45)	0.483
TB positive (ref: absent)	1.08 (0.74-1.58)	0.674
Neurological disorder (ref: absent)	1.48 (0.55-3.96)	0.219

WAZ weight-for-age Z-score

**Discussion** 

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

Our analysis revealed a high proportion of children aged 2 months to 14 years with severe pneumonia in Kenyan secondary-level health facilities had previously been admitted for care. Risk factors for re-hospitalisation for severe pneumonia are age >12months, moderate/severe undernutrition and neurological disorder. The proportion of children getting plain chest radiography, second line antibiotics, TB medication, salbutamol and prednisone was higher among those re-admitted compared to those hospitalised for the first time. Mortality among children hospitalised with severe pneumonia is high, but not significantly different among those readmitted compared to first admissions. Children who are <12 months, over 5 years, female, with moderate/severe undernutrition or anaemia are at a higher risk of dying.

Publications on severe pneumonia readmission in children in LMICs are limited. Converselv. financial incentives and penalties imposed by hospital readmission reduction programs seem to drive such studies in high income countries (HICs), more so among adults (28). Readmissions can be classified as early (≤30 days) or late (≥31 days) (29). Re-admissions that occur within 30-days often correspond to those that are potentially avoidable, most of which are direct or indirect complications of underlying comorbidities (30). These are the readmissions health facilities and insurance companies are keen on reducing, and which hospitals in HICs are subject to penalties if unacceptable thresholds are reached (31). Large longitudinal studies of various tertiary referral hospitals in the United States of America (USA), reported a 30-day lower respiratory infection specific re-admission rate and paediatric pneumonia specific re-admission rate of 2.7% (32) and 3.3% (5) respectively, almost four times lower than in our study. A more recent analysis conducted in the USA using the 2018 Nationwide Readmissions Database reported a 30-day severe pneumonia specific readmission rate among children of 8.7%, while the re-admission rate in children with nonsevere pneumonia was 4.7% (33). The lower estimates found in the USA may be attributed to the difference in income contexts, pneumonia definitions, and the fact that these were strictly 30-day outcomes. All the children in our analysis had severe pneumonia based on WHO

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

guidelines. Furthermore, we could only ascertain that they had a prior hospital admission but we could neither determine the reason for the initial admission nor compute the time from the first admission given the nature of the data. It is imperative to obtain this time variable in future studies to report on comparable data with regard to early and late pneumonia readmissions. Hospital re-admission may signal failure in the health system performance. However, its interpretation may be complicated by observed and unobserved differences in the clinical risk of patient populations and their survival rates. For example, health facilities with low childhood mortality may have a higher unobserved volume of sick children at risk of re-admission (34). In our study, mortality among children hospitalised with severe pneumonia was high, but not significantly different among those readmitted compared to first admissions. Indeed, hospital re-admissions are a more complex phenomenon than mortality, in that they arise from an "interplay among patient-, hospital-, community-, and environmental-level factors" (35). Comorbidities including neurological disorders and malnutrition, were risk factors for rehospitalisation for pneumonia similar to our study (5, 32). In a cross-sectional study conducted at a Canadian tertiary hospital including almost 3,000 children, Owayed et al reported that most children hospitalised with recurrent pneumonia have a predisposing factor, the most common being oropharyngeal incoordination (36). This is a plausible explanation for the fourfold increased risk with severe pneumonia re-hospitalisation observed in children with a neurological disorder in our study. It calls for a high index of suspicion among clinicians from the first point of patient contact and consideration of medical or surgical interventions early. Immunosuppressive conditions have also been identified as a risk factor for pneumonia readmission in children (33). Immunosuppression can be due to moderate/severe malnutrition which was significantly associated with readmission in this study. However, in this analysis, HIV was not associated with severe pneumonia readmission; perhaps due to timely initiation of antiretroviral therapy within prevention of mother-to-child transmission services (37). Patient data on other conditions that present with recurrent pneumonia such as primary

immunodeficiency, cystic fibrosis and primary ciliary dyskinesia that can lead to bronchiectasis

(38) were not available. Unlike our study, age less than 1 year (5, 32) and male gender (32) have been identified as risk factors for re-hospitalisation for pneumonia. This could reflect differences in our study population. Perhaps, older children living longer to have a pneumonia readmission; or no actual particular gender risk for pneumonia rehospitalisation. Prior respiratory syncytial virus lower respiratory tract infection (39), longer index hospitalisations (5, 33), complicated pneumonia (5), and hospital case volume and teaching status (33) were other risk factors for re-hospitalisation for pneumonia identified in the literature but were not measured in this study. These are important variables that need to be examined in future studies.

Interestingly, Baseer et al estimated that 11.4% of children admitted with pneumonia during a one-year study in Egypt had recurrent pneumonia defined as ≥2 episodes of radiographically confirmed pneumonia in a single year or ≥3 episodes at any time with a radiographic clearing of densities between attack (40). In this analysis, almost 20% of children had a chest radiograph, with a significantly higher frequency of requests among children who were readmitted compared to those admitted with pneumonia for the first time. Data on interval assessment of chest radiographs was not available. It may be useful in future studies to document chest radiography findings and ascertain if children readmitted with severe pneumonia have recurrent pneumonia/persistent pneumonia. Timely interventions could potentially reverse, prevent or better manage chronic lung disease (8, 41).

Similar to our findings, other studies conducted in similar epidemiological and geographical contexts, specifically Kilifi at the Kenyan coast, Bangladesh and India, have found malnutrition (42-44) and incomplete vaccination (45) to be associated with mortality in children with severe pneumonia. We found severe pallor to be associated with mortality in children severe pneumonia (44, 46), consistent with previous findings among children with non-severe pneumonia (6). This association in children with pneumonia may be indicative of a reduced threshold for respiratory decompensation in this vulnerable population. Timely identification

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

and management of anaemia is needed to prevent death in children hospitalised with severe pneumonia. Previous studies have described the association between higher mortality and infants with severe pneumonia (47), which we also found in our analysis. Interestingly, mortality in children over 5 years was similar to that observed among infants. Mortality among children aged 5-14 years has received little attention (48), with those in sub-Saharan Africa faring worse (49). Older children may have attendant complex comorbidities that put them at risk for death. Evidence-based treatment algorithms for this neglected population are needed. Moderate or severe malnutrition and neurological disorders in children with severe pneumonia should signal a need for post-admission follow up and potential re-admission. Optimizing nutrition may avert re-admission with severe pneumonia. Going forward, it will be important to conduct studies that objectively assess possible aspiration/reflux in children with neurological disorders readmitted with pneumonia in these settings perhaps using simple questionnaires at district-level health facilities (50) or/and more elaborate tests such as videofluoroscopic swallowing studies to assess swallowing (51) and scintigraphy, pH-metry and other studies to quantify gastro-oesophageal reflux in referral centres (52). Establishing the multi-disciplinary capacity necessary to improve care for children with neurologic disorders, specifically training physiotherapists and speech therapists is an urgent requirement. In this study, referral of patients with severe pneumonia who had been readmitted was guite low at 3%, similar to those with a first hospitalisation with pneumonia. It is difficult to ascertain whether clinicians are reluctant to refer patients; or whether patients would honour the referral instructions. Exploring referral systems in future studies may prompt changes in patient pathways for children with severe pneumonia who have been re-hospitalised. This may inform the health facilities on the areas that could be improved, which could include increasing the number of specialists and sub-specialists in the counties through models such as the African Paediatric Fellowship Program (53). Remote consultation (54), among other solutions that adopt a contextually appropriate reasoned diagnostic approach for children with

recurrent/persistent pneumonia may be considered (8).

To the best of our knowledge, this is the first published study to report on severe pneumonia rehospitalisation in children in sub-Saharan Africa. The large sample size across multiple settings provides a contemporary representation of paediatric severe pneumonia re-admission in a high burden context, offering a foundation for research and interventions averting or mitigating the clinical sequelae of pneumonia. The study is limited by its retrospective nature and use of routinely collected data, which may result in missing data on variables of interest, such as the interval between first admission and subsequent readmissions, challenges linking records for patients with multiple episodes of readmission, specialised modalities of testing employed (e.g., videofluoroscopy, echocardiography), and relevant complications (e.g., pleural effusions, abscess, air leaks).

#### Conclusion

The proportion of children re-hospitalised with severe pneumonia and their in-hospital mortality is high. Age, nutritional status and neurological disorder are risk factors of severe pneumonia recurrence; additionally, gender, incomplete vaccination and anaemia increase risk of mortality. Optimal care for severe pneumonia will require carefully designed studies of clinical algorithms for the screening, case management, and follow up of children, prioritising those with underlying risk factors.

List of abbreviations aHR - adjusted Hazard Ratio aOR - adjusted Odds Ratio CIN – Clinical Information Network KEMRI - Kenya Medical Research Institute LMIC – Low-and-middle-income country TB - tuberculosis WAZ – Weight-for-Age Z-score WHO - World Health Organization 

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

**Declarations** 

Ethics approval and consent to participate The Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit approved the collection of the deidentified data analysed in this study. The CIN is run in collaboration with the Ministry of Health and participating hospitals with the aim to improve the quality of routine paediatric hospital data for use in audits, observational and interventional research. Individual consent for access to deidentified patient data was not required. Consent for publication Not applicable. Availability of data and materials The data utilized in this work was made available to the research team by the participating hospitals and the Ministry of Health, and thus we are not the primary data owners; our use for these routine hospital data is approved as part of a specific ethical review process. Further access to the data can be sought through a request to KEMRI Wellcome Trust Research Programmes's Data Governance Committee through email: dgc@kemri-wellcome.org. Competing interests The authors declare that they have no competing interests. **Funding** The research reported is funded by a Joint Global Health Trials Award (MR/R006083/1) from the Department of Health and Social Care (DHSC), the Foreign, Commonwealth & Development Office (FCDO), the Medical Research Council (MRC) and the Wellcome Trust.

This UK funded award is part of the EDCTP2 programme supported by the European Union.

#### Authors' contributions

DM-B and AA conceived the study and DM-B performed the analysis with support from AA. DM drafted the initial manuscript with support from AA, PM, LI, TN, LM, DK, AA, EJ, AI, and CW. CIN authors contributed to the design of data collection tools, conduct of the work, collection of the data, and data quality assurance that form the basis of this manuscript. All

authors read and approved the final version of the manuscript.

## Acknowledgements

The authors would like to thank the Ministry of Health who gave permission for this work to be developed and have supported the implementation of the Clinical Information Network (CIN) together with the County Health Executives, Hospital Management Teams, the Kenya Paediatric Association, the Kenya Ministry of Health, and the University of Nairobi for promoting the aims of the CIN. Specifically, teams based in: Busia County Hospital (Emma Sarah Namulala, Yuvane Maiyo); Bungoma County Hospital (Dickens Lubanga, Felistus Makokha); Homabay County Hospital (Meshack Liru, Edith Ogada); Vihiga County Hospital (Vitalis Juma); JOOTRH (Josephine Ojigo, Maureen Muchela); Kakamega CGTRH (Boniface Nyumbile, Roselyn Malangachi, Ijusa Midecha); Kitale County Hospital (Rachel Inginia, Paul J W Njanwe, Mwende Mutunga); Kiambu County Hospital (Grace Ochieng, Lydia Thuranira and Catherine Murianki); Mama Lucy Kibaki Hospital (Cecilia Mutiso, Celia Muturi, Elizabeth Atieno Jowi); Machakos County Hospital (Charles Nzioki, Penina Musyoka); Kisumu County Hospital (Achieng Adem, Sharon Ocharo); Embu County Hospital (Esther Mukami Njiru, Mwangi Ngina, Patrick Lydia); Naivasha County Hospitals (Julie Barasa); Thika Level 5

Hospital (Bernadette Lusweti, Maureen Njoroge, Sylvia Mwathi, Patrick Mburugu); Nakuru County Hospital (Angeline Ithondeka, Linda Ombito, Alice Nkirote Nyaribari, Elizabeth Kibaru); Kerugoya County Hospital (Peninah Muthoni Mwangi); Mbagathi County Hospital (Christine Manyasi, David Kimutai, Rukia Aden, Zanuba Mohammed); Nyeri County Hospital (Wagura Mwangi, Agnes Mithamo); Pumwani Maternity Hospital (Catherine Mutinda, Beth Maina, Rashid Musa, Caren Emadau, Maureen Muirithi, Esther Muthoni Ogolla); Migori County Hospital (Joyce Akuka); Malindi Sub-County Hospital (Yusuf Rasheed); Kisii County Hospital (Mourine Ikol); and Karatina Sub-County Hospital (Stella Mbuga). The authors also acknowledge the other members of the CIN leadership: Jalemba Aluvaala, Anthony Etyang, Samuel Akech, Muthoni Ogola, Jacquie Oliwa, Michuki Maina, David Gathara, Fredrick Were, Grace Irimu, and Mike English, as well as technical and administrative assistance provided by Metrine Saisi, Elizabeth Muthini, James Wafula, Cynthia Khazenzi, Joyce Kigo, George Mbevi, Henry Gathuri, Wycliffe Nyachiro, and Frankline Oketch. This work is published with the permission of the Director of KEMRI CGMRC.

perpetuity.

It is made available under a CC-BY 4.0 International license .

#### References

626

- 627 1. Gray DM, Turkovic L, Willemse L, Visagie A, Vanker A, Stein DJ, et al. Lung
- 628 Function in African Infants in the Drakenstein Child Health Study. Impact of Lower
- Respiratory Tract Illness. Am J Respir Crit Care Med. 2017;195(2):212-20.
- 630 2. Gray D, Willemse L, Visagie A, Czovek D, Nduru P, Vanker A, et al. Determinants
- of early-life lung function in African infants. Thorax. 2017;72(5):445-50.
- 632 3. Hadning I, Andayani TM, Endarti D, Triasih R. Health-Related Quality of Life
- Among Children With Pneumonia in Indonesia Using the EuroQoL Descriptive System
- Value Set for Indonesia. Value Health Reg Issues. 2021;24:12-6.
- 4. Jackson P, Muyanja SZ, Siddharthan T. Health Equity and Respiratory Diseases in
- Low- and Middle-Income Countries. Clin Chest Med. 2023;44(3):623-34.
- 637 5. Neuman MI, Hall M, Gay JC, Blaschke AJ, Williams DJ, Parikh K, et al.
- Readmissions among children previously hospitalized with pneumonia. Pediatrics.
- 639 2014;134(1):100-9.
- 640 6. Macpherson L, Ogero M, Akech S, Aluvaala J, Gathara D, Irimu G, et al. Risk factors
- for death among children aged 5-14 years hospitalised with pneumonia: a retrospective cohort
- study in Kenya. BMJ Glob Health. 2019;4(5):e001715.
- 643 7. Ciftci E, Gunes M, Koksal Y, Ince E, Dogru U. Underlying causes of recurrent
- pneumonia in Turkish children in a university hospital. Journal of tropical pediatrics.
- 645 2003;49(4):212-5.
- 8. Montella S, Corcione A, Santamaria F. Recurrent Pneumonia in Children: A
- Reasoned Diagnostic Approach and a Single Centre Experience. Int J Mol Sci. 2017;18(2).
- Wald ER. Recurrent and nonresolving pneumonia in children. Semin Respir Infect.
- 649 1993;8(1):46-58.
- 650 10. Verwey C, Gray DM, Dangor Z, Ferrand RA, Ayuk AC, Marangu D, et al.
- Bronchiectasis in African children: Challenges and barriers to care. Frontiers in pediatrics.
- 652 2022;10:954608.
- Nathan N, Griese M, Michel K, Carlens J, Gilbert C, Emiralioglu N, et al. Diagnostic
- workup of childhood interstitial lung disease. Eur Respir Rev. 2023;32(167).
- Erjaee A, Bagherpour M, Van Rooyen C, Van den Berg S, Kinnear CJ, Green RJ, et
- al. Primary immunodeficiency in Africa a review. South African medical journal = Suid-
- Afrikaanse tydskrif vir geneeskunde. 2019;109(8b):3-11.
- Van Rensburg J, Alessandrini M, Stewart C, Pepper MS. Cystic fibrosis in South
- Africa: A changing diagnostic paradigm. South African medical journal = Suid-Afrikaanse
- 660 tydskrif vir geneeskunde. 2018;108(8):624-8.
- 661 14. Fassad MR, Shoman WI, Morsy H, Patel MP, Radwan N, Jenkins L, et al. Clinical
- and genetic spectrum in 33 Egyptian families with suspected primary ciliary dyskinesia. Clin Genet. 2020;97(3):509-15.
- 664 15. Ardura-Garcia C, Kuehni CE. Reducing childhood respiratory morbidity and
- 665 mortality in low and middle income countries: a current challenge. The European respiratory journal. 2019;54(1).
- 16. Nguyen PTK, Tran HT, Fitzgerald DA, Tran TS, Graham SM, Marais BJ.
- 668 Characterisation of children hospitalised with pneumonia in central Vietnam: a prospective
- study. The European respiratory journal. 2019;54(1).
- 670 17. Ardura-Garcia C, Stolbrink M, Zaidi S, Cooper PJ, Blakey JD. Predictors of repeated
- acute hospital attendance for asthma in children: A systematic review and meta-analysis.
- 672 Pediatric pulmonology. 2018;53(9):1179-92.
- 673 18. Organization WH. Pocket book of hospital care for children: guidelines for the
- management of common childhood illnesses: World Health Organization; 2013.

- 675 19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: 676
- guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. 677
- 678 20. English M, Irimu G, Agweyu A, Gathara D, Oliwa J, Ayieko P, et al. Building
- 679 Learning Health Systems to Accelerate Research and Improve Outcomes of Clinical Care in
- 680 Low- and Middle-Income Countries. PLoS Med. 2016;13(4):e1001991.
- 681 21. English M, Irimu G, Akech S, Aluvaala J, Ogero M, Isaaka L, et al. Employing
- 682 learning health system principles to advance research on severe neonatal and paediatric
- 683 illness in Kenya. BMJ Glob Health. 2021;6(3).
- 684 Avieko P, Ogero M, Makone B, Julius T, Mbevi G, Nyachiro W, et al. Characteristics
- 685 of admissions and variations in the use of basic investigations, treatments and outcomes in
- 686 Kenyan hospitals within a new Clinical Information Network. Archives of disease in
- 687 childhood. 2016;101(3):223-9.
- 688 Ministry of Health K. Basic Paediatric Protocols 2016 [4th Edition: [Available from:
- 689 http://guidelines.health.go.ke:8000/media/Basic Paediatric Protocols 2016.pdf.
- 690 Research Electronic Data Capture (REDCap) [Available from: https://www.project-24.
- 691 redcap.org/.
- 692 25. Austin PC, Merlo J. Intermediate and advanced topics in multilevel logistic regression
- 693 analysis. Statistics in medicine. 2017;36(20):3257-77.
- 694 26. Austin PC. A Tutorial on Multilevel Survival Analysis: Methods, Models and
- 695 Applications. Int Stat Rev. 2017;85(2):185-203.
- 696 Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations:
- 697 what is it and how does it work? Int J Methods Psychiatr Res. 2011;20(1):40-9.
- 698 Wallace SS, Quinonez RA. Solving the Readmissions Puzzle: How Do Variability 28.
- 699 and Preventability Fit? Pediatrics. 2017;140(2).
- 700 Prescott HC, Sjoding MW, Iwashyna TJ. Diagnoses of early and late readmissions
- 701 after hospitalization for pneumonia. A systematic review. Annals of the American Thoracic
- 702 Society. 2014;11(7):1091-100.
- 703 Donzé J, Lipsitz S, Bates DW, Schnipper JL. Causes and patterns of readmissions in
- 704 patients with common comorbidities: retrospective cohort study. Bmj. 2013;347:f7171.
- 705 Medicare To Penalize 2,217 Hospitals For Excess Readmissions. Kaiser Health News. 31.
- 706 2012 Oct 12 [press release].
- 707 32. Nakamura MM, Zaslavsky AM, Toomey SL, Petty CR, Bryant MC, Geanacopoulos
- 708 AT, et al. Pediatric Readmissions After Hospitalizations for Lower Respiratory Infections.
- 709 Pediatrics. 2017;140(2).
- 710 33. Lewis MO, Tran PT, Huang Y, Desai RA, Shen Y, Brown JD. Disease Severity and
- 711 Risk Factors of 30-Day Hospital Readmission in Pediatric Hospitalizations for Pneumonia.
- 712 Journal of clinical medicine. 2022;11(5).
- 713 Laudicella M, Li Donni P, Smith PC. Hospital readmission rates: signal of failure or
- 714 success? J Health Econ. 2013;32(5):909-21.
- 715 Weinreich M, Nguyen OK, Wang D, Mayo H, Mortensen EM, Halm EA, et al.
- 716 Predicting the Risk of Readmission in Pneumonia. A Systematic Review of Model
- 717 Performance. Annals of the American Thoracic Society. 2016;13(9):1607-14.
- 718 Owayed AF, Campbell DM, Wang EE. Underlying causes of recurrent pneumonia in 36.
- 719 children. Archives of pediatrics & adolescent medicine. 2000;154(2):190-4.
- 720 37. Mwau M, Bwana P, Kithinji L, Ogollah F, Ochieng S, Akinyi C, et al. Mother-to-
- 721 child transmission of HIV in Kenya: A cross-sectional analysis of the national database over
- 722 nine years. PLoS One. 2017;12(8):e0183860.
- Bush A, Floto RA. Pathophysiology, causes and genetics of paediatric and adult 723 38.
- 724 bronchiectasis. Respirology. 2019;24(11):1053-62.


perpetuity.

It is made available under a CC-BY 4.0 International license .


- 725 39. Munywoki PK, Ohuma EO, Ngama M, Bauni E, Scott JA, Nokes DJ. Severe lower
- respiratory tract infection in early infancy and pneumonia hospitalizations among children,
- 727 Kenya. Emerg Infect Dis. 2013;19(2):223-9.
- 728 40. Abdel Baseer KA, Sakhr H. Clinical profile and risk factors of recurrent pneumonia in
- children at Qena governorate, Egypt. Int J Clin Pract. 2021;75(4):e13695.
- 730 41. Patria F, Longhi B, Tagliabue C, Tenconi R, Ballista P, Ricciardi G, et al. Clinical
- profile of recurrent community-acquired pneumonia in children. BMC pulmonary medicine.
- 732 2013;13:60.
- 733 42. Chisti MJ, Graham SM, Duke T, Ahmed T, Faruque AS, Ashraf H, et al. Post-
- discharge mortality in children with severe malnutrition and pneumonia in Bangladesh. PLoS
- 735 One. 2014;9(9):e107663.
- 736 43. Ngari MM, Fegan G, Mwangome MK, Ngama MJ, Mturi N, Scott JAG, et al.
- 737 Mortality after Inpatient Treatment for Severe Pneumonia in Children: a Cohort Study.
- Paediatric and perinatal epidemiology. 2017;31(3):233-42.
- 739 44. Kapoor A, Awasthi S, Kumar Yadav K. Predicting Mortality and Use of RISC
- 740 Scoring System in Hospitalized Under-Five Children Due to WHO Defined Severe
- 741 Community Acquired Pneumonia. Journal of tropical pediatrics. 2022;68(4).
- 742 45. Kasundriya SK, Dhaneria M, Mathur A, Pathak A. Incidence and Risk Factors for
- Severe Pneumonia in Children Hospitalized with Pneumonia in Ujjain, India. International
- journal of environmental research and public health. 2020;17(13).
- 745 46. Tiewsoh K, Lodha R, Pandey RM, Broor S, Kalaivani M, Kabra SK. Factors
- determining the outcome of children hospitalized with severe pneumonia. BMC Pediatr.
- 747 2009;9:15.
- 748 47. Sonego M, Pellegrin MC, Becker G, Lazzerini M. Risk factors for mortality from
- acute lower respiratory infections (ALRI) in children under five years of age in low and
- 750 middle-income countries: a systematic review and meta-analysis of observational studies.
- 751 PLoS One. 2015;10(1):e0116380.
- 752 48. Patton GC, Azzopardi P. Missing in the middle: measuring a million deaths annually
- 753 in children aged 5-14 years. The Lancet Global health. 2018;6(10):e1048-e9.
- 754 49. Masquelier B, Hug L, Sharrow D, You D, Hogan D, Hill K, et al. Global, regional,
- and national mortality trends in older children and young adolescents (5-14 years) from 1990
- to 2016: an analysis of empirical data. The Lancet Global health. 2018;6(10):e1087-e99.
- 757 50. Duncan DR, DiFilippo C, Kane M, Lurie M, McSweeney ME, Rosen RL.
- 758 Overlapping Symptoms of Gastroesophageal Reflux and Aspiration Highlight the Limitations
- of Validated Questionnaires. Journal of pediatric gastroenterology and nutrition.
- 760 2021;72(3):372-7.
- 761 51. Martin-Harris B, Canon CL, Bonilha HS, Murray J, Davidson K, Lefton-Greif MA.
- 762 Best Practices in Modified Barium Swallow Studies. Am J Speech Lang Pathol.
- 763 2020;29(2s):1078-93.

771


- Rosen R. Novel Advances in the Evaluation and Treatment of Children With
- 765 Symptoms of Gastroesophageal Reflux Disease. Frontiers in pediatrics. 2022;10:849105.
- 766 53. Zar HJ, Vanker A, Gray D, Zampoli M. The African Pediatric Fellowship Training
- 767 Program in Pediatric Pulmonology: A Model for Growing African Capacity in Child Lung
- Health. Annals of the American Thoracic Society. 2017;14(4):500-4.
- 769 54. Ambrosino N, Makhabah DN, Sutanto YS. Tele-medicine in respiratory diseases.
- 770 Multidisciplinary respiratory medicine. 2017;12:9.




(A)




(B)




(C)



(D)



(E)



(F)

